Y-W Xu1,2, Y-H Peng1,2, L-Q Ran3, T-T Zhai4, H-P Guo5, S-Q Qiu6, H-L Chen7, Z-Y Wu7, E-M Li8,9, J-J Xie10,11. 1. Department of Clinical Laboratory Medicine, The Cancer Hospital of Shantou University Medical College, Shantou, China. 2. The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, China. 3. Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, China. 4. Department of Radiation Oncology, The Cancer Hospital of Shantou University Medical College, Shantou, China. 5. Department of Head and Neck Surgery, The Cancer Hospital of Shantou University Medical College, Shantou, China. 6. The Breast Center, The Cancer Hospital of Shantou University Medical College, Shantou, China. 7. Department of Surgical Oncology, Shantou Central Hospital, Shantou, China. 8. The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, China. nmli@stu.edu.cn. 9. Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, China. nmli@stu.edu.cn. 10. The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, China. g_jjxie@stu.edu.cn. 11. Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, China. g_jjxie@stu.edu.cn.
Abstract
BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a common malignant disease worldwide, especially in China. We aimed to determine the level of autoantibodies against L1CAM in patients with ESCC. METHODS: Levels of circulating autoantibodies against L1CAM antigens were determined by an enzyme-linked immunosorbent assay in cohort 1 (191 patients with ESCC and 94 normal controls) and validated in cohort 2 (47 patients with ESCC and 47 normal controls). Receiver-operating characteristics were employed to calculate diagnostic accuracy. Cumulative survival time was calculated by the Kaplan-Meier method and analyzed by the log-rank test. RESULTS: In cohorts 1 and 2, levels of autoantibodies against L1CAM were all significantly higher in sera of patients with ESCC compared to normal controls (P < 0.05). Detection of autoantibodies against L1CAM provided a sensitivity of 26.2%, a specificity of 90.4%, and an area under the curve (AUC) of 0.603 (95% CI 0.535-0.672) in diagnosing ESCC in cohort 1, and a sensitivity of 27.7%, a specificity of 91.5%, and an AUC of 0.628 (95% CI 0.516-0.741). Similar results were observed in the diagnosis of early stage ESCC (25.2% sensitivity, 90.4% specificity, and an AUC of 0.611 (95% CI 0.533-0.689) in cohort 1, and 33.3% sensitivity, 91.5% specificity, and an AUC of 0.636 (95% CI 0.439-0.832) in cohort 2). Moreover, positive rates of autoantibodies against L1CAM had no statistical correlation with clinical outcome of ESCC (P > 0.05). CONCLUSIONS: Our results suggest that circulating autoantibodies against L1CAM is a potential biomarker for the early detection of ESCC.
BACKGROUND:Esophageal squamous cell carcinoma (ESCC) is a common malignant disease worldwide, especially in China. We aimed to determine the level of autoantibodies against L1CAM in patients with ESCC. METHODS: Levels of circulating autoantibodies against L1CAM antigens were determined by an enzyme-linked immunosorbent assay in cohort 1 (191 patients with ESCC and 94 normal controls) and validated in cohort 2 (47 patients with ESCC and 47 normal controls). Receiver-operating characteristics were employed to calculate diagnostic accuracy. Cumulative survival time was calculated by the Kaplan-Meier method and analyzed by the log-rank test. RESULTS: In cohorts 1 and 2, levels of autoantibodies against L1CAM were all significantly higher in sera of patients with ESCC compared to normal controls (P < 0.05). Detection of autoantibodies against L1CAM provided a sensitivity of 26.2%, a specificity of 90.4%, and an area under the curve (AUC) of 0.603 (95% CI 0.535-0.672) in diagnosing ESCC in cohort 1, and a sensitivity of 27.7%, a specificity of 91.5%, and an AUC of 0.628 (95% CI 0.516-0.741). Similar results were observed in the diagnosis of early stage ESCC (25.2% sensitivity, 90.4% specificity, and an AUC of 0.611 (95% CI 0.533-0.689) in cohort 1, and 33.3% sensitivity, 91.5% specificity, and an AUC of 0.636 (95% CI 0.439-0.832) in cohort 2). Moreover, positive rates of autoantibodies against L1CAM had no statistical correlation with clinical outcome of ESCC (P > 0.05). CONCLUSIONS: Our results suggest that circulating autoantibodies against L1CAM is a potential biomarker for the early detection of ESCC.
Entities:
Keywords:
Autoantibodies; Diagnosis; Esophageal squamous cell carcinoma; L1CAM; Sera
Authors: Xiaoju Wang; Jianjun Yu; Arun Sreekumar; Sooryanarayana Varambally; Ronglai Shen; Donald Giacherio; Rohit Mehra; James E Montie; Kenneth J Pienta; Martin G Sanda; Philip W Kantoff; Mark A Rubin; John T Wei; Debashis Ghosh; Arul M Chinnaiyan Journal: N Engl J Med Date: 2005-09-22 Impact factor: 91.245
Authors: Arjun Pennathur; Andrew Farkas; Alyssa M Krasinskas; Peter F Ferson; William E Gooding; Michael K Gibson; Matthew J Schuchert; Rodney J Landreneau; James D Luketich Journal: Ann Thorac Surg Date: 2009-04 Impact factor: 4.330
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Verena Tischler; Marco Pfeifer; Silke Hausladen; Uwe Schirmer; Anne-Katrine Bonde; Glen Kristiansen; Martin L Sos; Walter Weder; Holger Moch; Peter Altevogt; Alex Soltermann Journal: Mol Cancer Date: 2011-10-10 Impact factor: 27.401